Clinician preferences for neurotechnologies in pediatric drug- resistant epilepsy: A discrete choice experiment

Pediatric
Written By Rodrigo Silva

Glory O. Apantaku, Patrick J. McDonald, Magda Aguiar, Laura Y. Cabrera, Winston Chiong, Mary B. Connolly, Viorica Hrincu, George M. Ibrahim, K. Julia Kaal, Ashley Lawson, Robert Naftel, Eric Racine, Abdollah Safari, Mark Harrison, Judy Illes

Epilepsia. 2022;00:1–12.
DOI: 10.1111/epi.17328 

This study by Apantaku et al. (Jun. 2022) examined clinicians’ #preferences for neuromodulation treatments in pediatric patients with drug-resistant epilepsy (#DRE).

The survey included 68 clinicians from the USA (74%) and Canada (26%): 33 neurosurgeons, 28 neurologists, and 7 other clinicians. The most important influence on clinicians’ preferences is the chance of clinically significant improvement in seizures. Vagus nerve stimulation (#VNS) had the highest priority among all the existing #neuromodulation treatments, while deep brain stimulation (#DBS) was the lowest.



Rodrigo Silva
Previous

Feasibility of video/audio monitoring in the analysis of motion and treatment effects on night-time seizures – Interventional study
Next

Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy